<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id><journal-id journal-id-type="publisher-id">cn</journal-id><journal-id journal-id-type="coden">acncdm</journal-id><journal-title-group><journal-title>ACS Chemical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1948-7193</issn><issn pub-type="epub">1948-7193</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25123416</article-id><article-id pub-id-type="pmc">4210126</article-id><article-id pub-id-type="doi">10.1021/cn500138n</article-id><article-categories><subj-group><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Synthesis and Evaluation of Translocator 18 kDa Protein
(TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding
Sensitivity to Human Single Nucleotide Polymorphism rs6971</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Zanotti-Fregonara</surname><given-names>Paolo</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Zhang</surname><given-names>Yi</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Jenko</surname><given-names>Kimberly J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Gladding</surname><given-names>Robert L.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Zoghbi</surname><given-names>Sami S.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Fujita</surname><given-names>Masahiro</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Sbardella</surname><given-names>Gianluca</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Castellano</surname><given-names>Sabrina</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Taliani</surname><given-names>Sabrina</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Martini</surname><given-names>Claudia</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Innis</surname><given-names>Robert B.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Da Settimo</surname><given-names>Federico</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath13"><name><surname>Pike</surname><given-names>Victor W.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Molecular
Imaging Branch, National Institute of Mental Health, <institution>National Institutes of Health</institution>, Bethesda, Maryland 20892-0001, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Pharmacy, <institution>University of Salerno</institution>, 84084 Fisciano (SA), <country>Italy</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Pharmacy, <institution>University of Pisa</institution>, Via Bonanno 6, 56126 Pisa, <country>Italy</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Tel.: <phone>+3015945986</phone>. Fax: <fax>+3014805112</fax>. E-mail: <email>pikev@mail.nih.gov</email>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>08</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2014</year></pub-date><pub-date pub-type="collection"><day>15</day><month>10</month><year>2014</year></pub-date><volume>5</volume><issue>10</issue><fpage>963</fpage><lpage>971</lpage><history><date date-type="received"><day>20</day><month>06</month><year>2014</year></date><date date-type="rev-recd"><day>14</day><month>08</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American
Chemical Society</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American
Chemical Society</copyright-holder><license><license-p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">Terms of Use</ext-link></license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0010" id="ab-tgr1"/></p><p>The imaging of translocator 18 kDa
protein (TSPO) in living human
brain with radioligands by positron emission tomography (PET) has
become an important means for the study of neuroinflammatory conditions
occurring in several neuropsychiatric disorders. The widely used prototypical
PET radioligand [<sup>11</sup>C](<italic>R</italic>)-PK 11195 ([<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold>; [<italic><italic>N</italic>-methyl</italic>-<sup>11</sup>C](<italic>R</italic>)-<italic>N</italic>-<italic>sec</italic>-butyl-1-(2-chlorophenyl)-<italic>N</italic>-methylisoquinoline-3-carboxamide) gives a low PET signal and is
difficult to quantify, whereas later generation radioligands have
binding sensitivity to a human single nucleotide polymorphism (SNP)
rs6971, which imposes limitations on their utility for comparative
quantitative PET studies of normal and diseased subjects. Recently,
azaisosteres of <bold>1</bold> have been developed with improved drug-like
properties, including enhanced TSPO affinity accompanied by moderated
lipophilicity. Here we selected three of these new ligands (<bold>7</bold>&#x02013;<bold>9</bold>) for labeling with carbon-11 and for
evaluation in monkey as candidate PET radioligands for imaging brain
TSPO. Each radioligand was readily prepared by <sup>11</sup>C-methylation
of an <italic>N</italic>-desmethyl precursor and was found to give
a high proportion of TSPO-specific binding in monkey brain. One of
these radioligands, [<sup>11</sup>C]<bold>7</bold>, the direct 4-azaisostere
of <bold>1</bold>, presents many radioligand properties that are superior
to those reported for [<sup>11</sup>C]<bold>1</bold>, including higher
affinity, lower lipophilicity, and stable quantifiable PET signal.
Importantly, <bold>7</bold> was also found to show very low sensitivity
to the human SNP rs6971 in vitro. Therefore, [<sup>11</sup>C]<bold>7</bold> now warrants evaluation in human subjects with PET to assess
its utility for imaging TSPO in human brain, irrespective of subject
genotype.</p></abstract><kwd-group><kwd>TSPO</kwd><kwd>PET</kwd><kwd>radioligand</kwd><kwd>carbon-11</kwd><kwd>imaging</kwd><kwd>brain</kwd></kwd-group><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cn500138n</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cn-2014-00138n</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Translocator protein 18 kDa
(TSPO), formerly known as the peripheral benzodiazepine receptor,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> is mainly located in outer mitochondrial membranes<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> and is implicated in several functions, including
cholesterol transport and stereoidogenesis.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> TSPO expression
is up-regulated in several human pathologies with inflammation, including
a large number of neuropsychiatric disorders that are known or suspected
to have inflammation.<sup><xref ref-type="bibr" rid="ref6">6</xref>&#x02212;<xref ref-type="bibr" rid="ref12">12</xref></sup> In neuroinflammatory conditions, TSPO is upregulated both in activated
microglia, which reflect an acute response to injury, and in reactive
astrocytes, which may accumulate to form a sclerosis (i.e., scar)
in brain and remain for life.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> Thus, PET imaging of
TSPO is keenly pursued for its ability to inform on the development
of neuroinflammatory conditions in brain and as a potential biomarker
in clinical trials with anti-inflammatory drugs.<sup><xref ref-type="bibr" rid="ref15">15</xref>&#x02212;<xref ref-type="bibr" rid="ref18">18</xref></sup></p><p>The prototypical radioligand,
[<sup>11</sup>C]PK11195 ([<sup>11</sup>C]<bold>1</bold>), first as
racemate<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> and later
as its higher affinity <italic>R-</italic>enantiomer ([<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold>, Figure <xref rid="fig1" ref-type="fig">1</xref>),<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> has been used for almost three decades for
imaging brain TSPO with PET. However, this radioligand is recognized
to have severe limitations, including low sensitivity and poor amenability
to quantification.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Consequently, considerable
efforts have been expended on developing improved radioligands,<sup><xref ref-type="bibr" rid="ref15">15</xref>&#x02212;<xref ref-type="bibr" rid="ref17">17</xref></sup> such as [<sup>11</sup>C]PBR28 ([<sup>11</sup>C]<bold>2</bold>),<sup><xref ref-type="bibr" rid="ref24">24</xref>&#x02212;<xref ref-type="bibr" rid="ref26">26</xref></sup> [<sup>18</sup>F]FBR ([<sup>18</sup>F]<bold>3</bold>),<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> [<sup>11</sup>C]DPA 713 ([<sup>11</sup>C]<bold>4</bold>),<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> [<sup>18</sup>F]PBR111 ([<sup>18</sup>F]<bold>5</bold>),<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> and [<sup>18</sup>F]FEPPA ([<sup>18</sup>F]<bold>6</bold>)<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> (Figure <xref rid="fig1" ref-type="fig">1</xref>). These radioligands deliver
higher TSPO-specific signals but suffer from sensitivity to the single
nucleotide polymorphism (SNP) rs6971, which has an allelic frequency
of about 30% in humans of European ancestry.<sup><xref ref-type="bibr" rid="ref30">30</xref>&#x02212;<xref ref-type="bibr" rid="ref34">34</xref></sup> This SNP, which has no known clinical significance,
is codominantly expressed, giving rise to high-affinity binders (HABs
that have two high-affinity alleles), low-affinity binders (LABs that
have two low affinity alleles), and mixed-affinity binders (MABs that
have one low- and one high-affinity allele). The differential affinity
of the two alleles can be large for some radioligands, for example,
about 50-fold difference in affinity for [<sup>11</sup>C]<bold>2</bold>. Depending on the radioligand, LABs have such negligible uptake
in brain that they must be excluded from PET study. In addition, HAB
and MAB subjects must be genotyped to correct for the effect of genotype
on binding. Therefore, an effective TSPO PET radioligand that is devoid
of sensitivity to SNP rs6971 would be valuable.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Structures of some known
TSPO PET radioligands and of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0001" id="gr1" position="float"/></fig><p>Despite its other limitations,
[<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold> shows exceptionally
low sensitivity to SNP rs697
in vitro,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> although it may have some sensitivity
in vivo.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> We recently reported a series
of 4-phenylquinazoline-2-carboxamides as TSPO ligands designed as
azaisosteres of <bold>1</bold>.<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> A wide number of variously
decorated derivatives were synthesized and biologically evaluated,
most of which showed high TSPO binding affinity with <italic>K</italic><sub>i</sub> values in the nanomolar/subnanomolar range and with
high selectivity toward the target protein. Specifically, three of
these ligands (<bold>7</bold>&#x02013;<bold>9</bold>) were considered
to present attractive properties for PET radioligand development,
including high TSPO affinity and moderate lipophilicity. Here we sought
to prepare the three radioligands [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> (Figure <xref rid="fig1" ref-type="fig">1</xref>) for evaluation of their
abilities to image TSPO in monkey brain. In view of our findings of
promising TSPO imaging characteristics for [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in monkey, we also used assays with human
leukocytes and postmortem human cerebellum to establish that their
TSPO binding characteristics were promising for PET imaging of all
TSPO genotypes.</p><sec id="sec2"><title>Results and Discussion</title><p>Our selection
of the three 4-phenylquinazoline-2-carboxamides <bold>7</bold>&#x02013;<bold>9</bold> for labeling with carbon-11 (&#x003b2;<sup>+</sup>, <italic>t</italic><sub>1/2</sub> = 20.4 min) and evaluation
as possible PET radioligands for brain TSPO was initially guided by
their high affinities toward TSPO and their computed moderate lipophilicities
(clogD values) (Table <xref rid="tbl1" ref-type="other">1</xref>), which are consistent
with achieving adequate brain entry and low nonspecific binding.<sup><xref ref-type="bibr" rid="ref37">37</xref>&#x02212;<xref ref-type="bibr" rid="ref40">40</xref></sup> In this regard, <bold>7</bold>&#x02013;<bold>9</bold> favorably presented
superior affinity and attenuated lipophilicity with respect to <bold>1</bold> (Table <xref rid="tbl1" ref-type="other">1</xref>). Here we found that these
three ligands were readily labeled with carbon-11 and showed high
TSPO-specific PET signals in rhesus monkey brain. In addition, they
were found to show low sensitivity to human TSPO genotype in vitro.
Overall, [<sup>11</sup>C]<bold>7</bold>, in particular, merits evaluation
in human subjects.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>In Silico and in Vitro Properties
of <bold>1</bold> and <bold>7</bold>&#x02013;<bold>9</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th colspan="2" align="center" char=".">HAB <italic>K</italic><sub>i</sub> (nM)<hr/></th><th colspan="2" align="center" char=".">LAB <italic>K</italic><sub>i</sub> (nM)<hr/></th><th colspan="2" align="center" char=".">LAB <italic>K</italic><sub>i</sub>/HAB <italic>K</italic><sub>i</sub><hr/></th><th style="border:none;" align="center" char=".">&#x000a0;</th></tr><tr><th style="border:none;" align="center">Ligand</th><th style="border:none;" align="center" char=".">Rat <italic>K</italic><sub>i</sub> (nM)<xref rid="t1fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" char=".">clogD</th><th style="border:none;" align="center" char=".">logD<xref rid="t1fn2" ref-type="table-fn">b</xref></th><th style="border:none;" align="center" char=".">Leukocytes<xref rid="t1fn3" ref-type="table-fn">c</xref></th><th style="border:none;" align="center" char=".">Cerebellum<xref rid="t1fn4" ref-type="table-fn">d</xref></th><th style="border:none;" align="center" char=".">Leukocytes<xref rid="t1fn3" ref-type="table-fn">c</xref></th><th style="border:none;" align="center" char=".">Cerebellum<xref rid="t1fn4" ref-type="table-fn">d</xref></th><th style="border:none;" align="center" char=".">Leukocytes</th><th style="border:none;" align="center" char=".">Cerebellum</th><th style="border:none;" align="center" char=".">LipE<xref rid="t1fn5" ref-type="table-fn">e</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">9.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td style="border:none;" align="char" char=".">3.72</td><td style="border:none;" align="char" char=".">3.97&#x000a0;&#x000b1;&#x000a0;0.18</td><td style="border:none;" align="char" char=".">4.06&#x000a0;&#x000b1;&#x000a0;1.20</td><td style="border:none;" align="char" char=".">4.53&#x000a0;&#x000b1;&#x000a0;2.08</td><td style="border:none;" align="char" char=".">3.94&#x000a0;&#x000b1;&#x000a0;1.20</td><td style="border:none;" align="char" char=".">4.16&#x000a0;&#x000b1;&#x000a0;0.89</td><td style="border:none;" align="char" char=".">0.97</td><td style="border:none;" align="char" char=".">0.92</td><td style="border:none;" align="char" char=".">4.37</td></tr><tr><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="char" char=".">3.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char=".">2.95</td><td style="border:none;" align="char" char=".">3.55&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="char" char=".">1.26&#x000a0;&#x000b1;&#x000a0;0.57</td><td style="border:none;" align="char" char=".">1.48&#x000a0;&#x000b1;&#x000a0;0.18</td><td style="border:none;" align="char" char=".">1.65&#x000a0;&#x000b1;&#x000a0;0.26</td><td style="border:none;" align="char" char=".">1.89&#x000a0;&#x000b1;&#x000a0;0.33</td><td style="border:none;" align="char" char=".">1.3</td><td style="border:none;" align="char" char=".">1.3</td><td style="border:none;" align="char" char=".">5.28</td></tr><tr><td style="border:none;" align="left"><bold>8</bold></td><td style="border:none;" align="char" char=".">2.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char=".">3.22</td><td style="border:none;" align="char" char=".">3.540&#x000a0;&#x000b1;&#x000a0;0.005</td><td style="border:none;" align="char" char=".">0.91&#x000a0;&#x000b1;&#x000a0;0.47</td><td style="border:none;" align="char" char=".">1.01&#x000a0;&#x000b1;&#x000a0;0.35</td><td style="border:none;" align="char" char=".">2.20&#x000a0;&#x000b1;&#x000a0;1.0</td><td style="border:none;" align="char" char=".">2.64&#x000a0;&#x000b1;&#x000a0;0.88</td><td style="border:none;" align="char" char=".">2.4</td><td style="border:none;" align="char" char=".">2.6</td><td style="border:none;" align="char" char=".">5.46</td></tr><tr><td style="border:none;" align="left"><bold>9</bold></td><td style="border:none;" align="char" char=".">3.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="char" char=".">2.54</td><td style="border:none;" align="char" char=".">2.98&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char=".">3.99&#x000a0;&#x000b1;&#x000a0;0.85</td><td style="border:none;" align="char" char=".">5.74&#x000a0;&#x000b1;&#x000a0;0.77</td><td style="border:none;" align="char" char=".">10.1&#x000a0;&#x000b1;&#x000a0;2.6</td><td style="border:none;" align="char" char=".">15.6&#x000a0;&#x000b1;&#x000a0;1.9</td><td style="border:none;" align="char" char=".">2.5</td><td style="border:none;" align="char" char=".">2.7</td><td style="border:none;" align="char" char=".">5.26</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>From ref (<xref ref-type="bibr" rid="ref35">35</xref>).</p></fn><fn id="t1fn2"><label>b</label><p>Mean &#x000b1; SD for <italic>n</italic> = 6.</p></fn><fn id="t1fn3"><label>c</label><p>Mean &#x000b1; SD for
leukocytes from
5 subjects, except 4 HAB subjects were used for <bold>9</bold>.</p></fn><fn id="t1fn4"><label>d</label><p>Mean &#x000b1; SD for cerebellum from
4 subjects.</p></fn><fn id="t1fn5"><label>e</label><p><italic>pK</italic><sub>i</sub> &#x02013;
logD for human cerebellum HAB.</p></fn></table-wrap-foot></table-wrap><sec id="sec2.1"><title>Radiochemistry</title><p>The three radioligands [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> were prepared rapidly by treating
the respective <italic>N</italic>-desmethyl analogs <bold>10</bold>&#x02013;<bold>12</bold> with [<sup>11</sup>C]methyl iodide in DMSO
with potassium hydroxide as base (Figure <xref rid="fig2" ref-type="fig">2</xref>).
Each radioligand was purified by reverse phase HPLC and formulated
for intravenous injection. HPLC analysis showed that each formulated
radioligand was obtained in high radiochemical purity (&#x0003e;99%), in
high
specific radioactivity (typically &#x0003e;55 GBq/&#x003bc;mol at end of
synthesis)
(Table <xref rid="tbl2" ref-type="other">2</xref>), and free of significant chemical
contaminants as judged by the absence of major unknown absorbance
peaks in HPLC analysis. Moreover, each formulated radioligand was
radiochemically stable for at least 2 h. Adequate activities (&#x0003e;90
MBq) were readily obtained for PET imaging in monkey.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Labeling of <bold>7</bold>&#x02013;<bold>9</bold> with carbon-11.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0002" id="gr2" position="float"/></fig><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Radiochemical Yields, Purities, and
Specific Activities of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Radioligand</th><th style="border:none;" align="center">Decay-corrected
radiochemical yield (%)</th><th style="border:none;" align="center">Radiochemical
purity (%)</th><th style="border:none;" align="center">Specific
radioactivity range at EOS<xref rid="t2fn1" ref-type="table-fn">a</xref>(GBq/&#x003bc;mol)</th></tr></thead><tbody><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>7</bold></td><td style="border:none;" align="left">17&#x02013;29</td><td style="border:none;" align="left">100</td><td style="border:none;" align="left">72.2&#x02013;203 (<italic>n</italic>&#x000a0;=&#x000a0;4)</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>8</bold></td><td style="border:none;" align="left">23&#x02013;28</td><td style="border:none;" align="left">100</td><td style="border:none;" align="left">79.6&#x02013;226 (<italic>n</italic>&#x000a0;=&#x000a0;4)</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>9</bold></td><td style="border:none;" align="left">18&#x02013;27</td><td style="border:none;" align="left">100</td><td style="border:none;" align="left">53.7&#x02013;329 (<italic>n</italic>&#x000a0;=&#x000a0;6)</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>End of synthesis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.2"><title>Lipophilicity Measurements</title><p>Measured radioligand logD
values were found, as expected, to be almost identical for the two
chloro isomers [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold>, namely &#x0223c;3.5, and appreciably higher than for the
nonchloro compound [<sup>11</sup>C]<bold>9</bold> (Table <xref rid="tbl1" ref-type="other">1</xref>). As expected, all three quinazoline radioligands
[<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> have lower lipophilicity
than the counterpart isoquinoline <bold>1</bold> (logD, 3.97), which
has one less ring nitrogen. Measured logD values are in fair agreement
with our computed values, upon which the selection of <bold>7</bold>&#x02013;<bold>9</bold> for further development as PET radioligands
was made.</p></sec><sec id="sec2.3"><title>PET Imaging of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in Monkeys</title><p>The ability of radioligands [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> to image brain TSPO was tested with
PET in rhesus monkeys, first after radioligand injection at baseline,
and second after preblocking TSPO with <bold>1</bold> (5 mg/kg, i.v.)
at about 5 min before injection of radioligand. Summed PET images
of monkey brain acquired after radioligand injection (Figure <xref rid="fig3" ref-type="fig">3</xref>) displayed a high level of radioactivity, especially
in the choroid plexus of the fourth ventricle. High uptake was also
seen in striatum and cerebellum, and to a lesser extent in cortical
regions. Scans from the corresponding preblock experiments showed
a very uniform and low distribution of radioactivity, consistent with
the absence of radioligand specific binding to TSPO (data not shown).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Sagittal
summed PET images of brain after intravenous injection
of the same monkey with [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> under baseline conditions. Arrows point to the choroid plexus
of the fourth ventricle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0003" id="gr3" position="float"/></fig><p>At baseline, [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> were estimated to have mean peak whole brain concentrations
of 2.0,
2.3, and 1.8 SUV at about 23, 30, and 10 min (all, <italic>n</italic> = 2), respectively (Figure <xref rid="fig4" ref-type="fig">4</xref>). This moderately
high uptake is comparable to that achieved with other prominent TSPO
radioligands, such as [<sup>11</sup>C]<bold>2</bold><sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and [<sup>18</sup>F]<bold>3</bold>.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Subsequent washout of radioactivity from all TSPO-containing
regions was slow, reducing to 86, 92, and 36% of the peak value at
60 min for [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold>, respectively
(Figure <xref rid="fig4" ref-type="fig">4</xref>). In TSPO preblock experiments, the
kinetics of brain radioactivity was strikingly different. Peak brain
radioactivity was much higher and earlier but declined much faster
than at baseline to reach a low terminal level (Figure <xref rid="fig4" ref-type="fig">4</xref>), thereby evidencing the TSPO receptor block in the brain.
These data together indicate a high proportion of radioligand specific
binding to brain TSPO in the baseline experiments.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>PET time-activity curves
in whole rhesus monkey brain following
intravenous injection of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> under baseline and TSPO-preblocked conditions. Data are
from a single monkey.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0004" id="gr4" position="float"/></fig><p>Regional brain time-activity curves for each radioligand
at baseline
and at preblock showed the same shape as the whole brain curves, with
the exception of the curve for the choroid plexus of the fourth ventricle
for [<sup>11</sup>C]<bold>9</bold> (Figure <xref rid="fig5" ref-type="fig">5</xref>). The positional isomers, [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold>, have very similar affinity and lipophilicity
in vitro (Table <xref rid="tbl1" ref-type="other">1</xref>) and gave very similar time-activity
curves under each condition, although brain uptake was somewhat higher
for [<sup>11</sup>C]<bold>8</bold>. For each radioligand at baseline,
peak radioactivities were highest in the choroid plexus of the fourth
ventricle, followed by putamen, cerebellum, and all other examined
regions (Figure <xref rid="fig5" ref-type="fig">5</xref>). In the preblock experiment
with each radioligand, regional time-activity curves were virtually
superimposed, with the exception of the choroid plexus curve for [<sup>11</sup>C]<bold>9</bold>, which remained higher than for other regions.
These data evidence equal nonspecific binding for [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold> in all regions and equal
nonspecific binding for [<sup>11</sup>C]<bold>9</bold> in all regions
except the choroid plexus of the fourth ventricle (Figure <xref rid="fig5" ref-type="fig">5</xref>).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Time-activity curves in brain regions of the same monkey
following
intravenous injection of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> under baseline and TSPO-blocked conditions. Key: Anterior
cingulate (&#x025b3;), cerebellum (&#x025a1;), choroid plexus of the
fourth ventricle (&#x025cf;); hippocampus (&#x025c7;), prefrontal cortex
(&#x025cb;), and putamen (&#x025bd;).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0005" id="gr5" position="float"/></fig><p>In some paired baseline and preblock PET experiments, a metabolite-corrected
arterial input function for unchanged radioligand was measured (see
below) and used with Logan graphical analysis<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> to derive a measurement of radioligand binding in terms of total
distribution volume, <italic>V</italic><sub>T</sub>.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Logan-<italic>V</italic><sub>T</sub> values for [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> determined for direct comparison
in cerebellum of a single monkey were found to be 11.3, 25.6, and
2.4 mL/cm<sup>3</sup> at baseline and 2.0, 3.3, and 1.4 mL/cm<sup>3</sup> at preblock, indicating 82, 87, and 42% TSPO specific binding
at baseline, respectively (Table <xref rid="tbl3" ref-type="other">3</xref>). <italic>V</italic><sub>S</sub>, the difference between baseline and preblock <italic>V</italic><sub>T</sub>, may be taken as a measure of specific binding. <italic>V</italic><sub>S</sub> values for [<sup>11</sup>C]<bold>7</bold> and
[<sup>11</sup>C]<bold>8</bold> are 9.3 and 22.3 mL/cm<sup>3</sup>,
which are substantially higher than the <italic>V</italic><sub><italic>S</italic></sub> value (&#x0223c;2 mL/cm<sup>3</sup>) found<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> for [<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold>. <italic>V</italic><sub>S</sub> for [<sup>11</sup>C]<bold>9</bold> is lower than that of [<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold>. These data do not take into account changes in
brain exposure to radioligand due to changes in plasma free fraction
between baseline and preblock conditions. After correction for measured
free fraction changes in the same monkey (Table <xref rid="tbl4" ref-type="other">4</xref>), estimates of TSPO specific binding at baseline became 88, 89,
and 78%, respectively (Table <xref rid="tbl3" ref-type="other">3</xref>). Clearly, [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold> have
appreciably greater <italic>V</italic><sub>T</sub>/<italic>f</italic><sub>P</sub> values than [<sup>11</sup>C]<bold>9</bold>. It was therefore
of interest to assess the duration of PET data that needs to be acquired
to obtain acceptably stable <italic>V</italic><sub>T</sub> values,
which are often considered to be values that are sustained within
90% of the terminal value. Figure <xref rid="fig6" ref-type="fig">6</xref> shows the
variation in cerebellar <italic>V</italic><sub>T</sub>&#x02019;s for
[<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold> with
respect to their estimation from increasing durations of PET data
acquired immediately following radioligand administration. At baseline,
both radioligands reach 90% of terminal values by about 70 min. Whereas
the curve for [<sup>11</sup>C]<bold>7</bold> appears to be almost
stabilized by 120 min, that for [<sup>11</sup>C]<bold>8</bold> appears
still to be rising steadily. Therefore, on this basis, [<sup>11</sup>C]<bold>7</bold> appears to have more favorable kinetics for quantifying
TSPO in monkey brain than [<sup>11</sup>C]<bold>8</bold>.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Estimation of TSPO Specific Binding
in Monkey Cerebellum from <italic>V</italic><sub>T</sub> at Baseline
and under Preblock Conditions, with and without Correction for Plasma
Free Fraction (<italic>f</italic><sub>P</sub>)<xref rid="tbl3-fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">Radioligand</th><th style="border:none;" align="center" char="."><italic>V</italic><sub>T</sub> at baseline (mL/cm<sup>3</sup>)</th><th style="border:none;" align="center" char="."><italic>V</italic><sub>T</sub> at preblock (mL/cm<sup>3</sup>)</th><th style="border:none;" align="center" char=".">Est of TSPO
specific binding<xref rid="t3fn1" ref-type="table-fn">b</xref> (%)</th><th style="border:none;" align="center" char="."><italic>V</italic><sub>T</sub>/<italic>f</italic><sub>P</sub> at baseline (mL/cm<sup>3</sup>)</th><th style="border:none;" align="center" char="."><italic>V</italic><sub>T</sub>/<italic>f</italic><sub>P</sub> at
preblock (mL/cm<sup>3</sup>)</th><th style="border:none;" align="center" char=".">Est of TSPO
specific binding<xref rid="t3fn2" ref-type="table-fn">c</xref> (%)</th></tr></thead><tbody><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>7</bold></td><td style="border:none;" align="char" char=".">11.3</td><td style="border:none;" align="char" char=".">2.0</td><td style="border:none;" align="char" char=".">82</td><td style="border:none;" align="char" char=".">141</td><td style="border:none;" align="char" char=".">17.2</td><td style="border:none;" align="char" char=".">88</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>8</bold></td><td style="border:none;" align="char" char=".">25.6</td><td style="border:none;" align="char" char=".">3.3</td><td style="border:none;" align="char" char=".">87</td><td style="border:none;" align="char" char=".">533</td><td style="border:none;" align="char" char=".">60</td><td style="border:none;" align="char" char=".">89</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>9</bold></td><td style="border:none;" align="char" char=".">2.4</td><td style="border:none;" align="char" char=".">1.4</td><td style="border:none;" align="char" char=".">42</td><td style="border:none;" align="char" char=".">34.8</td><td style="border:none;" align="char" char=".">7.5</td><td style="border:none;" align="char" char=".">78</td></tr></tbody></table><table-wrap-foot><fn id="tbl3-fn1"><label>a</label><p>All data are
from the same monkey.</p></fn><fn id="t3fn1"><label>b</label><p>From <italic>V</italic><sub>T</sub> values.</p></fn><fn id="t3fn2"><label>c</label><p>From <italic>V</italic><sub>T</sub>/<italic>f</italic><sub>P</sub> values.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Extraction
Efficiencies and Retention
Volumes of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> and
Their Radiometabolites in Reverse Phase HPLC Analysis and Time To
Reach Radioligand as Half Plasma Activity and Plasma Free Fractions
(<italic>f</italic><sub>P</sub>)<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th colspan="5" align="center" char=".">Retention volume (mL)<hr/></th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th></tr><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th colspan="4" align="center" char=".">Radiometabolite<hr/></th><th colspan="2" align="center" char=".">Time to reach radioligand as half plasma activity
(min)<hr/></th><th colspan="2" align="center" char="."><italic>f</italic><sub>P</sub><xref rid="t4fn2" ref-type="table-fn">c</xref><hr/></th></tr><tr><th style="border:none;" align="center">Radioligand</th><th style="border:none;" align="center" char=".">Extraction
efficiency (%)<xref rid="t4fn1" ref-type="table-fn">b</xref></th><th style="border:none;" align="center" char=".">Radioligand</th><th style="border:none;" align="center" char=".">A</th><th style="border:none;" align="center" char=".">B</th><th style="border:none;" align="center" char=".">C</th><th style="border:none;" align="center" char=".">D</th><th style="border:none;" align="center" char=".">Baseline</th><th style="border:none;" align="center" char=".">Preblock</th><th style="border:none;" align="center" char=".">Baseline</th><th style="border:none;" align="center" char=".">Preblock</th></tr></thead><tbody><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>7</bold></td><td style="border:none;" align="char" char=".">95.4&#x000a0;&#x000b1;&#x000a0;4.0</td><td style="border:none;" align="char" char=".">9.5&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="char" char=".">3.6&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">4.8&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">5.9&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">7.2&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="char" char=".">35.1</td><td style="border:none;" align="char" char=".">9.57</td><td style="border:none;" align="char" char=".">0.080&#x000a0;&#x000b1;&#x000a0;0.003</td><td style="border:none;" align="char" char=".">0.116&#x000a0;&#x000b1;&#x000a0;0.003</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>8</bold></td><td style="border:none;" align="char" char=".">94.7&#x000a0;&#x000b1;&#x000a0;5.3</td><td style="border:none;" align="char" char=".">11.0&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">4.0&#x000a0;&#x000b1;&#x000a0;1.3</td><td style="border:none;" align="char" char=".">5.4&#x000a0;&#x000b1;&#x000a0;1.1</td><td style="border:none;" align="char" char=".">7.0&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">8.2&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">69.3</td><td style="border:none;" align="char" char=".">13.9</td><td style="border:none;" align="char" char=".">0.048&#x000a0;&#x000b1;&#x000a0;0.003</td><td style="border:none;" align="char" char=".">0.055&#x000a0;&#x000b1;&#x000a0;0.005</td></tr><tr><td style="border:none;" align="left">[<sup>11</sup>C]<bold>9</bold></td><td style="border:none;" align="char" char=".">95.9&#x000a0;&#x000b1;&#x000a0;2.8</td><td style="border:none;" align="char" char=".">8.8&#x000a0;&#x000b1;&#x000a0;2.5</td><td style="border:none;" align="char" char=".">3.8&#x000a0;&#x000b1;&#x000a0;1.2</td><td style="border:none;" align="char" char=".">5.1&#x000a0;&#x000b1;&#x000a0;1.6</td><td colspan="2" align="char" char=".">6.5&#x000a0;&#x000b1;&#x000a0;1.9<xref rid="t4fn3" ref-type="table-fn">d</xref></td><td style="border:none;" align="char" char=".">26.0</td><td style="border:none;" align="char" char=".">9.4</td><td style="border:none;" align="char" char=".">0.069&#x000a0;&#x000b1;&#x000a0;0.004</td><td style="border:none;" align="char" char=".">0.186&#x000a0;&#x000b1;&#x000a0;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tbl4-fn1"><label>a</label><p>All data are
from the same monkey.</p></fn><fn id="t4fn1"><label>b</label><p>From
plasma into acetonitrile; mean
&#x000b1; SD for <italic>n</italic> = 34.</p></fn><fn id="t4fn2"><label>c</label><p>Mean &#x000b1; SD for <italic>n</italic> = 3.</p></fn><fn id="t4fn3"><label>d</label><p>C and D were not well resolved.</p></fn></table-wrap-foot></table-wrap><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Time-stability of volumes of distribution estimated
from Logan
analysis of PET data in the cerebellum of the same monkey after administration
of [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold> under baseline and TSPO preblock conditions. The <italic>x</italic>-axis is the duration of PET data acquired from the start of radioligand
administration that was used to calculate <italic>V</italic><sub>T</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0006" id="gr6" position="float"/></fig></sec><sec id="sec2.4"><title>Emergence of Radiometabolites
of [<sup>11</sup>C]<bold>7&#x02013;9</bold> in Monkey Plasma in Vivo</title><p>Generally, PET radioligands are
appreciably metabolized over the short time-span of a subject scanning
session. As seen above, quantitative analysis of radioligand kinetics
to derive output measures such as <italic>V</italic><sub>T</sub> may
require determination of the amount of unmetabolized radioligand in
plasma over the full duration of a scanning session. PET radioligands
that produce brain-penetrant radiometabolites are often difficult
to quantify.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> For these reasons, we assessed
the emergence of radiometabolites in monkey plasma following intravenous
administration of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold>.</p><p>The three radioligands were stable in whole blood and plasma
in vitro. Recoveries of radioactivity from monkey plasma into acetonitrile
for reverse phase HPLC analysis exceeded 94% (Table <xref rid="tbl4" ref-type="other">4</xref>). After administration of any of the three radioligands [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> into monkey, the percentage
of radioactivity in plasma represented by unchanged radioligand decreased
rapidly, and much more so in preblock experiments than in baseline
experiments with the same radioligand (Figure <xref rid="fig7" ref-type="fig">7</xref>). Thus, for [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold>, plasma radioactivity became composed equally of radiometabolites
and parent radioligand at 35.1, 69.3, and 26.0 min in baseline experiments
and at 9.57, 13.9, and 9.40 min in TSPO-preblock experiments in the
same monkey, respectively (Figure <xref rid="fig8" ref-type="fig">8</xref>, Table <xref rid="tbl4" ref-type="other">4</xref>). Moreover, the normalized concentrations of unchanged
radioligand in plasma (SUV) were much higher in the preblock experiments
than in the coupled baseline experiments (Figure <xref rid="fig7" ref-type="fig">7</xref>). Such differences have also been seen for other prominent
TSPO radioligands.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> The lower concentration of unchanged
radioligand in plasma in baseline experiments may be ascribed to a
depletion through binding to abundant TSPO receptors in peripheral
organs that does not occur under TSPO blocking conditions. The greater
plasma availability of unchanged radioligand under preblock conditions
likely explains the faster appearance of radiometabolites.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Time-courses
of concentration of unmetabolized [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in plasma after intravenous injection
into the same monkey under baseline and preblocked conditions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0007" id="gr7" position="float"/></fig><fig id="fig8" position="float"><label>Figure 8</label><caption><p>Time-courses of plasma radioactivity composition
in terms of parent
radioligand after i.v. administration of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> to the same monkey under baseline and TSPO
preblock conditions. The dotted lines intersect the curves when radiometabolites
become half the radioactivity in plasma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_0008" id="gr8" position="float"/></fig><p>For each radioligand, analyses of plasma from monkeys studied
at
baseline revealed four radiometabolites, all with shorter retention
times than the parent radioligand (Table <xref rid="tbl4" ref-type="other">4</xref>).
The identities of the radiometabolites are currently unknown, as are
their abilities to penetrate the blood-brain barrier.</p></sec><sec id="sec2.5"><title>Radioligand Plasma Free Fraction</title><p>Among other factors,
the radioligand plasma free fraction (<italic>f</italic><sub>P</sub>) has a strong influence on the ability of a radioligand to enter
the brain. Generally, it is assumed that only free radioligand in
plasma can enter the brain. The plasma free fractions of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in blood sampled from the
same monkey during baseline and preblock PET scans are shown in Table <xref rid="tbl4" ref-type="other">4</xref>. These are moderately low at baseline, ranging
from 0.048 for [<sup>11</sup>C]<bold>8</bold> to 0.080 for [<sup>11</sup>C]<bold>7</bold>, in accord with their moderate ligand lipophilicities
(measured logD values),<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> but substantially
higher than that of the more lipophilic [<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold> (<italic>f</italic><sub>P</sub>, 0.0207). Plasma
free fractions were much higher under preblock conditions than under
baseline conditions, especially for [<sup>11</sup>C]<bold>9</bold>.</p></sec><sec id="sec2.6"><title>Ligand Affinity to TSPO in Human Leukocytes and Human Cerebellum
in Vitro</title><p>As assessed in human leukocytes in vitro, ligands <bold>7</bold>&#x02013;<bold>9</bold>, respectively, showed high affinities
for human HAB TSPO (<italic>K</italic><sub>i</sub> = 1.26, 0.910,
and 3.99 nM; <italic>cf. K</italic><sub>i</sub> = 4.06 nM for <bold>1</bold>) and low ratios (1.3, 2.4, and 2.5; <italic>cf.</italic> 0.97 for <bold>1</bold>) of LAB to HAB TSPO affinity (Table <xref rid="tbl1" ref-type="other">1</xref>). An almost identical pattern of binding affinities
and of LAB to HAB binding affinity ratios emerged from assays on postmortem
human cerebellum (Table <xref rid="tbl1" ref-type="other">1</xref>). Although the cerebellum
assays were conducted at 37 &#x000b0;C and the leukocyte assays at room
temperature, <italic>K</italic><sub>i</sub> values were very similar.
Again, among <bold>7</bold>&#x02013;<bold>9</bold>, ligand <bold>7</bold> showed the lowest ratio (1.3) of LAB to HAB TSPO affinity. We estimate
that if a similar binding affinity ratio applied in PET studies of
human subjects of Caucasian ancestry in vivo, the likely error in
estimating binding potential without genotype correction would be
about 7% (see <xref rid="notes-1" ref-type="notes">Supporting Information</xref>).</p><p>For ligands <bold>7</bold>&#x02013;<bold>9</bold>, the ratios of HAB
TSPO affinity in cerebellum to measured lipophilicity (logD), as captured
in the LipE<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> scores (5.28, 5.46, and 5.26,
respectively), are appreciably superior to that of <bold>1</bold> (4.37)
(Table <xref rid="tbl1" ref-type="other">1</xref>). The high LipE scores for [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> are consistent with the high
proportions of TSPO-specific binding found in the monkey brain imaging
(Table <xref rid="tbl3" ref-type="other">3</xref>).</p><p>In summary, among a wide series
of 4-phenylquinazoline-2-carboxamide
azaisosters of <bold>1</bold>, recently reported as potent TSPO ligands,<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> three derivatives (<bold>7</bold>&#x02013;<bold>9</bold>) were selected
for PET radioligand development in view of their high TSPO affinity
and moderate lipophilicity. [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> were each easily prepared and readily entered monkey brain
to give a high proportion of specific binding to brain TSPO. As a
PET radioligand in monkey, unlike [<sup>11</sup>C]<bold>8</bold> and
[<sup>11</sup>C]<bold>9</bold>, [<sup>11</sup>C]<bold>7</bold> has
an array of favorable properties which are as good as or better than
those of [<sup>11</sup>C](<italic>R</italic>)-<bold>1</bold>.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> These include lower lipophilicity, higher free
fraction, higher LipE score, higher HAB TSPO affinity, similar very
low genotype sensitivity in vitro, higher TSPO-specific signal, higher
proportion of TSPO-specific binding, and better amenability to quantification
without highly problematic radiometabolites.</p><p>In conclusion,
[<sup>11</sup>C]<bold>7</bold> warrants further
evaluation in human subjects and in particular to determine whether
the very low sensitivity seen in vitro is reflected in vivo. We have
previously found that [<sup>11</sup>C]<bold>1</bold> has significant
in vivo sensitivity in peripheral organs between LABs and a combined
group of HABs and MABs.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Thus, a discrepancy
between in vitro and in vivo sensitivity may also exist for [<sup>11</sup>C]<bold>7</bold>. Imaging with [<sup>11</sup>C]<bold>7</bold> both in brain and in peripheral organs of humans will be the critical
test of its sensitivity to rs6971 and of its potential utility as
a biomarker of inflammatory disorders.</p></sec></sec><sec sec-type="methods" id="sec3"><title>Methods</title><sec id="sec3.1"><title>Materials
and Methods</title><p>All reagents were obtained from
commercial sources (Sigma-Aldrich; St Louis, MO). All solvents were
analytical grade. Racemic [<sup>3</sup>H]<bold>1</bold> (specific
activity, 3.14 GBq/&#x003bc;mol) was purchased from PerkinElmer Life
Sciences (Waltham, MA). Human blood samples were obtained under approval
from the Intramural Review Board of the National Institutes of Health.</p><p>&#x003b3;-Radioactivity from <sup>11</sup>C was measured using a
calibrated dose calibrator (Atomlab 300; Biodex Medical Systems, Inc.;
Shirley, NY). Radioactivity measurements were corrected for physical
decay. All radiochemistry was performed in lead-shielded hot-cells
for personnel protection from radiation.</p><p>Ligands <bold>7</bold>&#x02013;<bold>9</bold> and their <italic>N</italic>-desmethyl analogs <bold>10</bold>&#x02013;<bold>12</bold> were prepared as described previously.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></p></sec><sec id="sec3.2"><title>Assay of Ligands for Affinity to Human Leukocyte
TSPO Genotypes</title><p>Ligands <bold>7</bold>&#x02013;<bold>9</bold> were subjected to
receptor binding assays at room temperature in human leukocyte homogenates<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> with [<sup>3</sup>H]<bold>1</bold> as radioligand
to characterize ligand binding sensitivities to TSPO polymorphism.
Blood samples were obtained under National Institutes of Health IRB
approval and after obtaining consent from study participants. <italic>K</italic><sub>i</sub> values were measured in triplicate in five
high-affinity (HABs) and five low-affinity (LABs) binding tissues
whose affinity status had been predetermined. As a control in each
assay, a self-displacement assay was used to calculate the <italic>K</italic><sub>D</sub> of <bold>1</bold>. A mean <italic>K</italic><sub>D</sub> value of 4.7 nM<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> was then
used as the dissociation constant for <bold>1</bold> to calculate
ligand <italic>K</italic><sub>i</sub>.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Nonlinear regression curve-fitting software (GraphPad Prism 5; GraphPad
Software; San Diego, CA) was used to fit data to a one-site model
to provide ligand <italic>K</italic><sub>i</sub> values.</p></sec><sec id="sec3.3"><title>Assay of Ligands
for Affinity to Human Cerebellum TSPO Genotypes</title><p>Ligands <bold>7</bold>&#x02013;<bold>9</bold> were also subjected
to receptor binding assays in postmortem healthy human cerebellum
homogenates with [<sup>3</sup>H]<bold>1</bold> as radioligand to characterize
ligand binding sensitivities to the TSPO polymorphism. <italic>K</italic><sub>i</sub> values were measured in triplicate in four high-affinity
(HABs) and four low-affinity (LABs) cerebellum tissues whose affinity
status had been predetermined by genotype. Binding assays were performed
in a similar manner to those in leukocytes, except assays were incubated
for 1 h at 37 &#x000b0;C. As a control in each assay, a self-displacement
assay was used to calculate the <italic>K</italic><sub>D</sub> of <bold>1</bold>. A mean <italic>K</italic><sub>D</sub> value of 4.35 nM
was then used as the dissociation constant for <bold>1</bold> to calculate
ligand <italic>K</italic><sub>i</sub>.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Nonlinear regression curve-fitting software (GraphPad Prism 5; GraphPad
Software; San Diego, CA) was used to fit data to a one-site model
to provide ligand <italic>K</italic><sub>i</sub> values.</p></sec><sec id="sec3.4"><title>Production
of NCA [<sup>11</sup>C]Carbon Dioxide</title><p>No-carrier-added
(NCA) [<sup>11</sup>C]carbon dioxide (&#x0223c;85 GBq) was produced
with a PETtrace cyclotron (GE Medical Systems; Milwaukee, WI) according
to the <sup>14</sup>N(p,&#x003b1;)<sup>11</sup>C reaction<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> by irradiation of nitrogen gas (initial pressure
160 psi; 75 mL volume) containing 1% oxygen with a proton beam (16.5
MeV, 45 &#x003bc;A) for 40 min.</p></sec><sec id="sec3.5"><title>Radiochemistry</title><p>All radiochemistry was performed in
an upgraded<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> PLC-controlled apparatus
based on an original semirobotic Synthia instrument<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> (Synthia AB; Uppsala, Sweden), housed within a lead-shielded
hot-cell for personnel protection.</p><sec id="sec3.5.1"><title>Production of NCA [<sup>11</sup>C]Methyl Iodide</title><p>NCA
[<sup>11</sup>C]methyl iodide was produced from NCA [<sup>11</sup>C]carbon dioxide via reduction to [<sup>11</sup>C]methane and then
vapor phase iodination.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> Thus, at the
end of the proton irradiation, [<sup>11</sup>C]carbon dioxide was
delivered to a PETtrace MeI Process Module (GE Medical Systems; Severna
Park, MD) through stainless tubing (OD 1/8 in, ID 1/16 in) over 2
min and trapped on molecular sieve (13X) and reduced to [<sup>11</sup>C]methane over nickel at 360 &#x000b0;C. The [<sup>11</sup>C]methane
was recirculated over iodine at 720 &#x000b0;C to generate [<sup>11</sup>C]methyl iodide, which was trapped on Porapak Q held in the recirculation
path.</p></sec><sec id="sec3.5.2"><title>Radiosynthesis of [<sup>11</sup>C]<bold>7</bold></title><p>[<sup>11</sup>C]Iodomethane in carrier helium (15 mL/min) was bubbled into
a 1 mL V-vial containing the secondary amide precursor <bold>10</bold> (0.6 mg) and KOH (1.2 mg) in DMSO (0.4 mL). When the radioactivity
in the vial had maximized, the reaction mixture was sealed and heated
at 80 &#x000b0;C for 5 min and then diluted with water. The reaction
mixture was then injected onto an XTerra RP18 column (10 &#x003bc;m;
7.8 mm &#x000d7; 300 mm; Waters Corp.; Columbia, MD) eluted at 8 mL/min
with MeCN: 1 mM aq. NH<sub>4</sub>OH (37:63 v/v). [<sup>11</sup>C]<bold>7</bold> (<italic>t</italic><sub>R</sub>, ca. 15.3 min) was collected
in a 50-mL flask. This solution was concentrated to dryness by rotary
evaporation under reduced pressure and heat (80 &#x000b0;C). The radioactive
residue was formulated in sterile physiological saline (0.9% w/v;
10 mL) containing ethanol (5% v/v), and filtered through a sterile
filter (0.2 &#x003bc;m pore size, Millex-MP, 25 mm; Millipore, Billerica,
MA) into a sterile, pyrogen-free dose vial.</p><p>Formulated [<sup>11</sup>C]<bold>7</bold> (<italic>t</italic><sub>R</sub>, ca. 7.3
min) was analyzed for radiochemical and chemical purity on an Xterra
RP18 column (5 &#x003bc;m, 4.6 mm &#x000d7; 250 mm; Waters Corp.) eluted
with MeCN: 10 mM aq. NH<sub>4</sub>OH (56:44 v/v) at 1.5 mL/min with
eluate monitored for radioactivity (pin diode detector; Bioscan Inc.;
Washington, DC) and absorbance at 235 nm. A sample was injected onto
HPLC alone, and in a subsequent analysis along with authentic <bold>7</bold> to check for coelution. Product identity was further confirmed
by LC-MS/MS of associated carrier on a Finnigan LCQ DECA instrument
(ThermoFisher Scientific; Rockville, MD).</p></sec><sec id="sec3.5.3"><title>Radiosynthesis of [<sup>11</sup>C]<bold>8</bold></title><p>[<sup>11</sup>C]<bold>8</bold> was
prepared as described for [<sup>11</sup>C]<bold>7</bold>, except that
the reaction mixture consisted of secondary
amide precursor <bold>11</bold> (1.0 mg) and KOH (1.0 mg) in DMSO
(0.4 mL), and the HPLC separation was conducted with a mobile phase
of MeCN: 10 mM aq. NH<sub>4</sub>OH (41:59, v/v) ([<sup>11</sup>C]<bold>8</bold>; <italic>t</italic><sub>R</sub>, ca. 14.4 min).</p><p>[<sup>11</sup>C]<bold>8</bold> (<italic>t</italic><sub>R</sub>, ca. 6.8
min) was analyzed as described for [<sup>11</sup>C]<bold>7</bold>,
except that the HPLC mobile phase was MeCN: 1 mM aq. NH<sub>4</sub>OH (58:42 v/v).</p></sec><sec id="sec3.5.4"><title>Radiosynthesis of [<sup>11</sup>C]<bold>9</bold></title><p>[<sup>11</sup>C]<bold>9</bold> was prepared as described
for [<sup>11</sup>C]<bold>7,</bold> except that the reaction mixture
consisted of secondary
amide precursor <bold>12</bold> (1.0 mg) and KOH (3.0 mg) in DMSO
(0.4 mL), and that the HPLC separation was conducted with a mobile
phase of MeCN: 10 mM aq. NH<sub>4</sub>OH (38:62, v/v) ([<sup>11</sup>C]<bold>9</bold>; <italic>t</italic><sub>R</sub>, ca. 10.4 min).</p><p>[<sup>11</sup>C]<bold>9</bold> was analyzed as described for [<sup>11</sup>C]<bold>7</bold>, except that the mobile phase was MeCN:10
mM aq. NH<sub>4</sub>OH (55:45 v/v) and the absorbance detector was
set to read at 254 nm ([<sup>11</sup>C]<bold>9</bold>; <italic>t</italic><sub>R</sub>, ca. 6.0 min).</p></sec></sec><sec id="sec3.6"><title>Computation of cLogD</title><p>cLogD (at pH 7.4) values for <bold>7</bold>&#x02013;<bold>9</bold> were computed with Pallas for Windows
software version 3.8 in default mode (CompuDrug International; Bal
Harbor, FL).</p></sec><sec id="sec3.7"><title>Measurement of LogD</title><p>LogD (at pH
7.4) was measured on
each radioligand by partition between <italic>n</italic>-octanol and
sodium phosphate buffer (pH 7.4) at room temperature, as described
in detail previously.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup></p></sec><sec id="sec3.8"><title>PET Experiments
with [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in Monkeys</title><p>PET scans were performed in six male
rhesus (<italic>Macaca mulatta</italic>) monkeys (8.7&#x02013;11.1
kg). All animals were handled in accordance with the <italic>Guide
for the Care and Use of Laboratory Animals</italic>(<xref ref-type="bibr" rid="ref50">50</xref>) and the National Institute of Health Animal Care and Use
Committee. For each scanning session, the subject monkey was immobilized
with ketamine (10 mg/kg; i.m.) and maintained under anesthesia with
1&#x02013;3% isoflurane and 98.4% oxygen. Head position was fixed with
a stereotactic frame. An intravenous perfusion line, filled with saline
(0.9% w/v), was used for bolus injection of radioligand of 99.9% radiochemical
purity. Dynamic PET images of brain radioactivity were obtained for
up to 120 min on a microPET Focus F220 scanner (Siemens Medical Solutions
Inc.; Knoxville, TN), with frame durations ranging from 30 s to 5
min. All PET images were corrected for attenuation and scatter.</p><p>Baseline scans were performed with each radioligand in two (for [<sup>11</sup>C]<bold>7</bold> and [<sup>11</sup>C]<bold>8</bold>) or three
(for [<sup>11</sup>C]<bold>9</bold>) monkeys, one of which, weighing
between 10.7 and 11.1 kg, was used in separate sessions for all three
radioligands. Radioligands (165&#x02013;217 MBq) were administered
with low carrier mass doses of 1.27&#x02013;5.4 nmol/kg. Each baseline
scan was paired with a TSPO preblock scan at least 3 h later in the
same monkey in which the TSPO ligand <bold>1</bold> (5 mg/kg, i.v.)
was administered at 15 min before a second injection of the same radioligand
(175&#x02013;253 MBq; carrier dose 3.3&#x02013;6.7 nmol/kg).</p><sec id="sec3.8.1"><title>Image Analysis</title><p>PET Images were reconstructed using
Fourier rebinning plus two-dimensional filtered back-projection. An
averaged PET image was created by averaging all frames of PET images.
The averaged PET image was normalized to a standardized monkey MRI
template using SPM8 (Wellcome Trust Centre; London, UK), and the transformation
parameters were applied to the normalization of the individual PET
frames. A predefined atlas of volumes of interest was then applied
to the normalized dynamic scan to obtain decay-corrected time-activity
curves for several brain regions, namely amygdala, anterior cingulate,
basofrontal cortex, caudate, cerebellum, hippocampus, hypothalamus,
insula, lateral temporal cortex, medial temporal cortex, midbrain,
parietal cortex, occipital cortex, pons, posterior cingulate, prefrontal
cortex, putamen, temporal cortex, and thalamus. The choroid plexus
of the fourth ventricle was not defined in the atlas and was manually
defined for each monkey. Regional radioactivity levels were normalized
for injected dose and monkey weight and expressed as a standardized
uptake value (SUV):<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn-2014-00138n_m001" position="anchor"/></disp-formula></p></sec><sec id="sec3.8.2"><title>PET Data Analysis</title><p>Total distribution volumes (<italic>V</italic><sub>T</sub>)<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> were estimated
for different regions by Logan graphical analysis<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> using the PET brain time-activity curves and the measured
metabolite-corrected arterial input function. The temporal stabilities
of <italic>V</italic><sub>T</sub> in cerebellum in the baseline and
preblock experiments were assessed by estimating <italic>V</italic><sub>T</sub> from progressively time-truncated data sets. The PET
data analysis was performed using PMOD (PMOD Technologies Ltd.; Zurich,
Switzerland).</p></sec></sec><sec id="sec3.9"><title>Stability of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in Buffer and in Monkey Whole Blood and Plasma
in Vitro</title><p>The stability of each formulated radioligand to
incubation in sodium
phosphate buffer (0.15 M, pH 7.4) for 2 h at room temperature was
assessed by reverse phase radio-HPLC analysis. Each formulated radioligand
(110&#x02013;150 kBq; &#x0223c;5 &#x003bc;L) was also incubated for 45
min at room temperature in either whole monkey blood or plasma (0.5
mL). A sample (0.3 mL) was removed from whole blood and added to water
(0.4 mL) to lyse blood cells. Then the plasma (0.35 mL) or lysed cells
were added to acetonitrile (0.8 mL), and centrifuged. Then the supernatant
liquid was analyzed by reverse phase radio-HPLC on a Novapak C18 column
(4 &#x003bc;m; 8 &#x000d7; 100 mm; Waters Corp.) eluted at 2.5 mL/min with
MeOH/H<sub>2</sub>O/Et<sub>2</sub>O (75:25:0.1 by vol.).</p></sec><sec id="sec3.10"><title>Plasma Protein
Binding of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold>.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup></title><p>Each radioligand
was added to pooled human plasma, placed at the top of an &#x0201c;Amicon&#x0201d;
Centrifree filter unit (200 &#x003bc;L/unit) and filtered by ultracentrifugation
at 5000 &#x000d7; <italic>g</italic>. Then all components of filter units
were counted for radioactivity to allow calculation of radioligand
plasma protein binding (<italic>f</italic><sub>P</sub>).</p></sec><sec id="sec3.11"><title>Emergence
of Radiometabolites of [<sup>11</sup>C]<bold>7</bold>&#x02013;<bold>9</bold> in Monkey Plasma In Vivo</title><p>During a
baseline and a following preblock PET scan with each radioligand,
blood samples were drawn periodically from the monkey femoral artery
and collected in heparin-treated Vacutainer tubes. The samples were
centrifuged and the plasma separated. A sample of plasma (0.45 mL)
was mixed with acetonitrile (0.72 mL) and centrifuged. The supernatant
liquid was analyzed with radio-HPLC on a Novapak C18 column (4 &#x003bc;m;
8 &#x000d7; 100 mm; Waters Corp.) eluted with MeOH/H<sub>2</sub>O/Et<sub>2</sub>O (75:25:0.1 by vol.). Time-courses for percentages of radioactivity
in plasma represented by unchanged radioligand and its radiometabolites
were then calculated.</p></sec></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>Binding curves from ligand
assays on leukocytes and human cerebellar tissue, and estimation of
binding potential error in human for [<sup>11</sup>C]<bold>7</bold>, without genotype correction. This material is available free of
charge via the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org/">http://pubs.acs.org/</uri>.</p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cn500138n_si_001.pdf"><caption><p>cn500138n_si_001.pdf</p></caption></media></supplementary-material></sec><notes id="notes-5"><title>Author Contributions</title><p>S.T., C.M.,
F.D.S., R.B.I., and V.W.P. conceived the project. P.Z.-F., S.S.Z.,
M.F., K.J. J., R.B.I., and V.W.P. designed the experiments. P.Z.-F.,
Y.Z ., K.J. J., R.L.G., S.S.Z., and M.F. performed the experiments.
G.S., S.C., S.T., C.M., and F.D.S. contributed ligands and precursors.
P.Z.-F., K.J.J., S.S.Z., M.F., R.B.I., and V.W.P. performed data analyses.
P.Z.-F., Y.Z., S.S.Z, K.J.J., C.M., F.D.S., and V.W.P. wrote the manuscript.
All authors edited and approved the final version of the manuscript.</p></notes><notes id="NOTES-d13843e2976-autogenerated" notes-type="funding-statement"><p>This study was supported
by the Intramural Research Program of the National Institutes of Health
(NIH), specifically the National Institute of Mental Health (NIMH),
and MIUR (PRIN 2009, Futuro in Ricerca 2010, PRIN 2011).</p></notes><notes id="NOTES-d13843e2991-autogenerated" notes-type="conflict-of-interest"><p>The authors declare the
following competing financial interest(s): Drs. Pike, Innis, Zhang,
Zoghbi, Castellano, Da Settimo, Martini, and Taliani are named as
applicants on a U.S. patent appication with regard to the subject
of this publication.</p></notes><ack><title>Acknowledgments</title><p>We thank PMOD Technologies
Ltd. (Zurich, Switzerland), for
providing PMOD software to analyze PET data. We also thank Mr. David
T. Clark for effective assistance with experiments in plasma.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>HAB</term><def><p>high-affinity
binder</p></def></def-item><def-item><term>LAB</term><def><p>low-affinity
binder</p></def></def-item><def-item><term>MAB</term><def><p>mixed-affinity
binder</p></def></def-item><def-item><term>NCA</term><def><p>no-carrier-added</p></def></def-item><def-item><term>PET</term><def><p>positron emission
tomography</p></def></def-item><def-item><term>TSPO</term><def><p>translocator protein (18 kDa)</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Papadopoulos</surname><given-names>V.</given-names></name>; <name><surname>Baraldi</surname><given-names>M.</given-names></name>; <name><surname>Guilarte</surname><given-names>T. R.</given-names></name>; <name><surname>Knudsen</surname><given-names>T. B.</given-names></name>; <name><surname>Lacapere</surname><given-names>J. J.</given-names></name>; <name><surname>Lindemann</surname><given-names>P.</given-names></name>; <name><surname>Norenberg</surname><given-names>M. D.</given-names></name>; <name><surname>Nutt</surname><given-names>D.</given-names></name>; <name><surname>Weizman</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Gavish</surname><given-names>M.</given-names></name> (<year>2006</year>) <article-title>Translocator protein (18 kDa): new
nomenclature for the peripheral-type benzodiazepine receptor based
on its structure and molecular function</article-title>. <source>Trends
Pharmacol. Sci.</source>
<volume>27</volume>, <fpage>402</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">16822554</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Doble</surname><given-names>A.</given-names></name>; <name><surname>Malgouris</surname><given-names>C.</given-names></name>; <name><surname>Daniel</surname><given-names>M.</given-names></name>; <name><surname>Daniel</surname><given-names>N.</given-names></name>; <name><surname>Imbault</surname><given-names>F.</given-names></name>; <name><surname>Basbaum</surname><given-names>A.</given-names></name>; <name><surname>Uzan</surname><given-names>A.</given-names></name>; <name><surname>Gu&#x000e9;r&#x000e9;my</surname><given-names>C.</given-names></name>; <name><surname>Le Fur</surname><given-names>G.</given-names></name> (<year>1987</year>) <article-title>Labelling of peripheral-type benzodiazepine binding
sites in human brain with [<sup>3</sup>H]PK 11195: anatomical and
subcellular distribution</article-title>. <source>Brain Res. Bull.</source>
<volume>18</volume>, <fpage>49</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">3030512</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Casellas</surname><given-names>P.</given-names></name>; <name><surname>Galiegue</surname><given-names>S.</given-names></name>; <name><surname>Basile</surname><given-names>A. S.</given-names></name> (<year>2002</year>) <article-title>Peripheral
benzodiazepine receptors
and mitochondrial function</article-title>. <source>Neurochem. Int.</source>
<volume>40</volume>, <fpage>475</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">11850104</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Papadopoulos</surname><given-names>V.</given-names></name>; <name><surname>Lecanu</surname><given-names>L.</given-names></name>; <name><surname>Brown</surname><given-names>R. C.</given-names></name>; <name><surname>Han</surname><given-names>Z.</given-names></name>; <name><surname>Yao</surname><given-names>Z.-X.</given-names></name> (<year>2006</year>) <article-title>Peripheral-type
benzodiazepine receptor in neurosteroid biosynthesis, neuropathology
and neurological disorders</article-title>. <source>Neuroscience</source>
<volume>138</volume>, <fpage>749</fpage>&#x02013;<lpage>756</lpage>.<pub-id pub-id-type="pmid">16338086</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Rone</surname><given-names>M. B.</given-names></name>; <name><surname>Ran</surname><given-names>J.</given-names></name>; <name><surname>Papadopoulos</surname><given-names>V.</given-names></name> (<year>2009</year>) <article-title>Cholesterol
transport in steroid biosynthesis: role
of protein-protein interactions and implications in disease states</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1791</volume>, <fpage>646</fpage>&#x02013;<lpage>658</lpage>.<pub-id pub-id-type="pmid">19286473</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Veenman</surname><given-names>L.</given-names></name>; <name><surname>Gavish</surname><given-names>M.</given-names></name> (<year>2000</year>) <article-title>Peripheral benzodiazepine receptors: their implication
in brain disease</article-title>. <source>Drug Dev. Res.</source>
<volume>50</volume>, <fpage>355</fpage>&#x02013;<lpage>370</lpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Cagnin</surname><given-names>A.</given-names></name>; <name><surname>Brooks</surname><given-names>D. J.</given-names></name>; <name><surname>Kennedy</surname><given-names>A. M.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Myers</surname><given-names>R.</given-names></name>; <name><surname>Turkheimer</surname><given-names>F. E.</given-names></name>; <name><surname>Jones</surname><given-names>T.</given-names></name>; <name><surname>Banati</surname><given-names>R. B.</given-names></name> (<year>2001</year>) <article-title>In-vivo measurement
of activated microglia in dementia</article-title>. <source>Lancet</source>
<volume>358</volume>, <fpage>461</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">11513911</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Ouchi</surname><given-names>Y.</given-names></name>; <name><surname>Yoshikawa</surname><given-names>E.</given-names></name>; <name><surname>Sekine</surname><given-names>Y.</given-names></name>; <name><surname>Futatsubashi</surname><given-names>M.</given-names></name>; <name><surname>Kanno</surname><given-names>T.</given-names></name>; <name><surname>Ogusu</surname><given-names>T.</given-names></name>; <name><surname>Torizuka</surname><given-names>T.</given-names></name> (<year>2005</year>) <article-title>Microglial activation
and dopamine terminal loss in early Parkinson&#x02019;s disease</article-title>. <source>Ann. Neurol.</source>
<volume>57</volume>, <fpage>168</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">15668962</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Debruyne</surname><given-names>J. C.</given-names></name>; <name><surname>Versijpt</surname><given-names>J.</given-names></name>; <name><surname>Van Laere</surname><given-names>K. J.</given-names></name>; <name><surname>De Vos</surname><given-names>F.</given-names></name>; <name><surname>Keppens</surname><given-names>J.</given-names></name>; <name><surname>Strijckmans</surname><given-names>K.</given-names></name>; <name><surname>Achten</surname><given-names>E.</given-names></name>; <name><surname>Slegers</surname><given-names>G.</given-names></name>; <name><surname>Dierckx</surname><given-names>R. A.</given-names></name>; <name><surname>Korf</surname><given-names>J.</given-names></name>; <name><surname>De Reuck</surname><given-names>J. L.</given-names></name> (<year>2003</year>) <article-title>PET visualization of microglia in
multiple sclerosis patients using [<sup>11</sup>C]PK11195</article-title>. <source>Eur. J. Neurol.</source>
<volume>10</volume>, <fpage>257</fpage>&#x02013;<lpage>264</lpage>.<pub-id pub-id-type="pmid">12752399</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Chelli</surname><given-names>B.</given-names></name>; <name><surname>Pini</surname><given-names>S.</given-names></name>; <name><surname>Abelli</surname><given-names>M.</given-names></name>; <name><surname>Cardini</surname><given-names>A.</given-names></name>; <name><surname>Lari</surname><given-names>L.</given-names></name>; <name><surname>Muti</surname><given-names>M.</given-names></name>; <name><surname>Gesi</surname><given-names>C.</given-names></name>; <name><surname>Cassano</surname><given-names>G. B.</given-names></name>; <name><surname>Lucacchini</surname><given-names>A.</given-names></name>; <name><surname>Martini</surname><given-names>C.</given-names></name> (<year>2008</year>) <article-title>Platelet 18 kDa translocator protein density is reduced
in depressed patients with adult separation anxiety</article-title>. <source>Eur. Neuropsychopharmacol.</source>
<volume>18</volume>, <fpage>249</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">18054208</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Dell&#x02019;Osso</surname><given-names>L.</given-names></name>; <name><surname>Da Pozzo</surname><given-names>E.</given-names></name>; <name><surname>Carmassi</surname><given-names>C.</given-names></name>; <name><surname>Trincavelli</surname><given-names>M. L.</given-names></name>; <name><surname>Ciapparelli</surname><given-names>A.</given-names></name>; <name><surname>Martini</surname><given-names>C.</given-names></name> (<year>2010</year>) <article-title>Lifetime manic-hypomanic symptoms
in post-traumatic stress disorder: relationship with the 18 kDa mitochondrial
translocator protein density</article-title>. <source>Psychiatry Res.</source>
<volume>177</volume>, <fpage>139</fpage>&#x02013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">20363031</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Kreisl</surname><given-names>W. C.</given-names></name>; <name><surname>Lyoo</surname><given-names>C. H.</given-names></name>; <name><surname>McGwier</surname><given-names>M.</given-names></name>; <name><surname>Snow</surname><given-names>J.</given-names></name>; <name><surname>Jenko</surname><given-names>K. J.</given-names></name>; <name><surname>Kimura</surname><given-names>N.</given-names></name>; <name><surname>Corona</surname><given-names>W.</given-names></name>; <name><surname>Morse</surname><given-names>C. L.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>McMahon</surname><given-names>F. J.</given-names></name>; <name><surname>Turner</surname><given-names>R. S.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; (<year>2013</year>) <article-title><italic>In vivo</italic> radioligand
binding to translocator protein correlates with severity of Alzheimer&#x02019;s
disease</article-title>. <source>Brain</source>
<volume>136</volume>, <fpage>2228</fpage>&#x02013;<lpage>2238</lpage>.<pub-id pub-id-type="pmid">23775979</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Benavides</surname><given-names>J.</given-names></name>; <name><surname>Fage</surname><given-names>D.</given-names></name>; <name><surname>Carter</surname><given-names>C.</given-names></name>; <name><surname>Scatton</surname><given-names>B.</given-names></name> (<year>1987</year>) <article-title>Peripheral type benzodiazepine
binding sites are a sensitive indirect index of neuronal damage</article-title>. <source>Brain Res.</source>
<volume>421</volume>, <fpage>167</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">2891401</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Chen</surname><given-names>M.-K.</given-names></name>; <name><surname>Guilarte</surname><given-names>T. R.</given-names></name> (<year>2008</year>) <article-title>Translocator protein 18 kDa (TSPO): molecular sensor
of brain injury and repair</article-title>. <source>Pharmacol. Ther.</source>
<volume>118</volume>, <fpage>1</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">18374421</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Chaveau</surname><given-names>F.</given-names></name>; <name><surname>Boutin</surname><given-names>H.</given-names></name>; <name><surname>Van Camp</surname><given-names>N.</given-names></name>; <name><surname>Doll&#x000e8;</surname><given-names>F.</given-names></name>; <name><surname>Tavitian</surname><given-names>B.</given-names></name> (<year>2008</year>) <article-title>Nuclear imaging of neuroinflammation:
a comprehensive
review of [<sup>11</sup>C]PK11195 challengers</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source>
<volume>35</volume>, <fpage>2304</fpage>&#x02013;<lpage>2319</lpage>.<pub-id pub-id-type="pmid">18828015</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Doll&#x000e8;</surname><given-names>F.</given-names></name>; <name><surname>Luus</surname><given-names>C.</given-names></name>; <name><surname>Reynolds</surname><given-names>A.</given-names></name>; <name><surname>Kassiou</surname><given-names>M.</given-names></name> (<year>2009</year>) <article-title>Radiolabelled molecules
for imaging the translocator protein (18 kDa) using positron emission
tomography</article-title>. <source>Curr. Med. Chem.</source>
<volume>16</volume>, <fpage>2899</fpage>&#x02013;<lpage>2923</lpage>.<pub-id pub-id-type="pmid">19689272</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Schweitzer</surname><given-names>P. J.</given-names></name>; <name><surname>Fallon</surname><given-names>B. A.</given-names></name>; <name><surname>Mann</surname><given-names>J. J.</given-names></name>; <name><surname>Kumar</surname><given-names>J. S. D.</given-names></name> (<year>2010</year>) <article-title>PET
tracers for
the peripheral benzodiazepine receptor and uses thereof</article-title>. <source>Drug Discovery Today</source>
<volume>15</volume>, <fpage>933</fpage>&#x02013;<lpage>942</lpage>.<pub-id pub-id-type="pmid">20800696</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Venneti</surname><given-names>S.</given-names></name>; <name><surname>Lopresti</surname><given-names>B. J.</given-names></name>; <name><surname>Wiley</surname><given-names>C. A.</given-names></name> (<year>2006</year>) <article-title>The peripheral benzodiazepine receptor
(translocator protein 18 kDa) in microglia: from pathology to imaging</article-title>. <source>Prog. Neurobiol.</source>
<volume>80</volume>, <fpage>308</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">17156911</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Camsonne</surname><given-names>R.</given-names></name>; <name><surname>Moulin</surname><given-names>M. A.</given-names></name>; <name><surname>Crouzel</surname><given-names>C.</given-names></name>; <name><surname>Syrota</surname><given-names>A.</given-names></name>; <name><surname>Maziere</surname><given-names>M.</given-names></name>; <name><surname>Comar</surname><given-names>D.</given-names></name> (<year>1986</year>) <article-title><sup>11</sup>C-Labeling of PK 11195 and visualization of peripheral
receptors of benzodiazepines by positron emission tomography</article-title>. <source>J. Pharmacologie</source>
<volume>17</volume>, <fpage>383</fpage>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Petit-Tabou&#x000e9;</surname><given-names>M. C.</given-names></name>; <name><surname>Baron</surname><given-names>J. C.</given-names></name>; <name><surname>Barr&#x000e9;</surname><given-names>L.</given-names></name>; <name><surname>Travere</surname><given-names>J. M.</given-names></name>; <name><surname>Speckel</surname><given-names>D.</given-names></name>; <name><surname>Camsonne</surname><given-names>R.</given-names></name>; <name><surname>MacKenzie</surname><given-names>E. T.</given-names></name> (<year>1991</year>) <article-title>Brain kinetics and specific binding
of [<sup>11</sup>C]PK11195 to &#x003c9;<sub>3</sub> sites in baboon</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>200</volume>, <fpage>347</fpage>&#x02013;<lpage>351</lpage>.<pub-id pub-id-type="pmid">1782994</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Shah</surname><given-names>F.</given-names></name>; <name><surname>Hume</surname><given-names>S. P.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>Ashworth</surname><given-names>S.</given-names></name>; <name><surname>McDermott</surname><given-names>J.</given-names></name> (<year>1994</year>) <article-title>Synthesis
of the enantiomers of [<italic>N-methyl</italic>-<sup>11</sup>C]PK
11195 and comparison of their behaviours as radioligands for PK binding
sites in rats</article-title>. <source>Nucl. Med. Biol.</source>
<volume>21</volume>, <fpage>573</fpage>&#x02013;<lpage>581</lpage>.<pub-id pub-id-type="pmid">9234314</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Banati</surname><given-names>R. B.</given-names></name>; <name><surname>Goerres</surname><given-names>G. W.</given-names></name>; <name><surname>Myers</surname><given-names>R.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Turkheimer</surname><given-names>F. E.</given-names></name>; <name><surname>Kreutzberg</surname><given-names>G. W.</given-names></name>; <name><surname>Brooks</surname><given-names>D. J.</given-names></name>; <name><surname>Jones</surname><given-names>T.</given-names></name>; <name><surname>Duncan</surname><given-names>J. S.</given-names></name> (<year>1999</year>) <article-title>[<sup>11</sup>C](<italic>R</italic>)-PK11195 positron emission tomography imaging
of activated microglia in vivo in Rasmussen&#x02019;s encephalitis</article-title>. <source>Neurology</source>
<volume>53</volume>, <fpage>2199</fpage>&#x02013;<lpage>2203</lpage>.<pub-id pub-id-type="pmid">10599809</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Kreisl</surname><given-names>W. C.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Fujimura</surname><given-names>Y.</given-names></name>; <name><surname>Kimura</surname><given-names>N.</given-names></name>; <name><surname>Jenko</surname><given-names>K. J.</given-names></name>; <name><surname>Kannan</surname><given-names>P.</given-names></name>; <name><surname>Hong</surname><given-names>J.</given-names></name>; <name><surname>Morse</surname><given-names>C. L.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Gladding</surname><given-names>R. L.</given-names></name>; <name><surname>Jacobson</surname><given-names>S.</given-names></name>; <name><surname>Oh</surname><given-names>U.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name> (<year>2010</year>) <article-title>Comparison of [<sup>11</sup>C](<italic>R</italic>)-PK
11195 and [<sup>11</sup>C]PBR28, two radioligands for translocator
protein (18 kDa) in human and monkey: implications for positron emission
tomographic imaging of this inflammation biomarker</article-title>. <source>NeuroImage</source>
<volume>49</volume>, <fpage>2924</fpage>&#x02013;<lpage>2932</lpage>.<pub-id pub-id-type="pmid">19948230</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Briard</surname><given-names>E.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Imaizumi</surname><given-names>M.</given-names></name>; <name><surname>Gourley</surname><given-names>J. P.</given-names></name>; <name><surname>Shetty</surname><given-names>H. U.</given-names></name>; <name><surname>Hong</surname><given-names>J.</given-names></name>; <name><surname>Cropley</surname><given-names>V.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name> (<year>2008</year>) <article-title>Synthesis and evaluation in monkey of two sensitive <sup>11</sup>C-labeled aryloxyanilide ligands for imaging brain peripheral
benzodiazepine receptors in vivo</article-title>. <source>J. Med. Chem.</source>
<volume>51</volume>, <fpage>17</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">18067245</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Imaizumi</surname><given-names>M.</given-names></name>; <name><surname>Briard</surname><given-names>E.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Gourley</surname><given-names>J. P.</given-names></name>; <name><surname>Hong</surname><given-names>J.</given-names></name>; <name><surname>Fujimura</surname><given-names>Y.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name> (<year>2008</year>) <article-title>Brain and
whole-body imaging in nonhuman primates of [<sup>11</sup>C]PBR28,
a promising PET radioligand for peripheral benzodiazepine receptors</article-title>. <source>NeuroImage</source>
<volume>39</volume>, <fpage>1289</fpage>&#x02013;<lpage>1298</lpage>.<pub-id pub-id-type="pmid">18024084</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Imaizumi</surname><given-names>M.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Fujimura</surname><given-names>Y.</given-names></name>; <name><surname>Farris</surname><given-names>A. G.</given-names></name>; <name><surname>Suhara</surname><given-names>T.</given-names></name>; <name><surname>Hong</surname><given-names>J.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name> (<year>2008</year>) <article-title>Kinetic
analysis in healthy humans of a novel positron emission tomography
radioligand to image the peripheral benzodiazepine receptor, a potential
biomarker for inflammation</article-title>. <source>NeuroImage</source>
<volume>40</volume>, <fpage>43</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">18093844</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Briard</surname><given-names>E.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Sim&#x000e9;on</surname><given-names>F.</given-names></name>; <name><surname>Imaizumi</surname><given-names>M.</given-names></name>; <name><surname>Gourley</surname><given-names>J. P.</given-names></name>; <name><surname>Shetty</surname><given-names>H. U.</given-names></name>; <name><surname>Lu</surname><given-names>S.-Y.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name> (<year>2009</year>) <article-title>Single-step high-yield
radiosynthesis and evaluation
of a selective <sup>18</sup>F-labeled ligand for imaging brain peripheral
benzodiazepine receptors with PET</article-title>. <source>J. Med. Chem.</source>
<volume>52</volume>, <fpage>688</fpage>&#x02013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">19119848</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Endres</surname><given-names>C. J.</given-names></name>; <name><surname>Pomper</surname><given-names>M. G.</given-names></name>; <name><surname>James</surname><given-names>M.</given-names></name>; <name><surname>Uzuner</surname><given-names>O.</given-names></name>; <name><surname>Hammoud</surname><given-names>D. A.</given-names></name>; <name><surname>Watkins</surname><given-names>C. C.</given-names></name>; <name><surname>Reynolds</surname><given-names>A.</given-names></name>; <name><surname>Hilton</surname><given-names>J.</given-names></name>; <name><surname>Dannals</surname><given-names>R. F.</given-names></name>; <name><surname>Kassiou</surname><given-names>M.</given-names></name> (<year>2009</year>) <article-title>Initial evaluation
of [<sup>11</sup>C]DPA-713, a novel
TSPO PET ligand, in humans</article-title>. <source>J. Nucl. Med.</source>
<volume>50</volume>, <fpage>1276</fpage>&#x02013;<lpage>1282</lpage>.<pub-id pub-id-type="pmid">19617321</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Guo</surname><given-names>Q.</given-names></name>; <name><surname>Colasanti</surname><given-names>A.</given-names></name>; <name><surname>Owen</surname><given-names>D. R.</given-names></name>; <name><surname>Onega</surname><given-names>M.</given-names></name>; <name><surname>Kamalakaran</surname><given-names>A.</given-names></name>; <name><surname>Bennacef</surname><given-names>I.</given-names></name>; <name><surname>Matthews</surname><given-names>P. M.</given-names></name>; <name><surname>Rabiner</surname><given-names>E. A.</given-names></name>; <name><surname>Turkheimer</surname><given-names>F. E.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name> (<year>2013</year>) <article-title>Quantification of the specific translocator protein
signal of <sup>18</sup>F-PBR111 in healthy humans: a genetic polymorphism
effect on in vivo binding</article-title>. <source>J. Nucl. Med.</source>
<volume>54</volume>, <fpage>1915</fpage>&#x02013;<lpage>1923</lpage>.<pub-id pub-id-type="pmid">24071511</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Mizrahi</surname><given-names>R.</given-names></name>; <name><surname>Rusjan</surname><given-names>P. M.</given-names></name>; <name><surname>Kennedy</surname><given-names>J.</given-names></name>; <name><surname>Pollock</surname><given-names>B.</given-names></name>; <name><surname>Mulsant</surname><given-names>B.</given-names></name>; <name><surname>Suridjan</surname><given-names>I.</given-names></name>; <name><surname>De Luca</surname><given-names>V.</given-names></name>; <name><surname>Wilson</surname><given-names>A. A.</given-names></name>; <name><surname>Houle</surname><given-names>S.</given-names></name> (<year>2012</year>) <article-title>Translocator
protein (18 kDa) polymorphism (rs6971) explains <italic>in-vivo</italic> brain binding affinity of the PET radioligand [<sup>18</sup>F]-FEPPA</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>32</volume>, <fpage>968</fpage>&#x02013;<lpage>972</lpage>.<pub-id pub-id-type="pmid">22472607</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Owen</surname><given-names>D. R.</given-names></name>; <name><surname>Howell</surname><given-names>O. W.</given-names></name>; <name><surname>Tang</surname><given-names>S.-P.</given-names></name>; <name><surname>Wells</surname><given-names>L. A.</given-names></name>; <name><surname>Bennacef</surname><given-names>I.</given-names></name>; <name><surname>Bergstrom</surname><given-names>M.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Rabiner</surname><given-names>E. A.</given-names></name>; <name><surname>Wilkins</surname><given-names>M. R.</given-names></name>; <name><surname>Reynolds</surname><given-names>R.</given-names></name>; <name><surname>Matthews</surname><given-names>P. M.</given-names></name>; <name><surname>Parker</surname><given-names>C. A.</given-names></name> (<year>2010</year>) <article-title>Two binding sites
for [<sup>3</sup>H]PBR28 in human brain: implications for TSPO PET
imaging of neuroinflammation</article-title>. <source>J. Cerebr. Blood
Flow Metab.</source>
<volume>30</volume>, <fpage>1608</fpage>&#x02013;<lpage>1618</lpage>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Kreisl</surname><given-names>W.
C.</given-names></name>; <name><surname>Jenko</surname><given-names>K. J.</given-names></name>; <name><surname>Hines</surname><given-names>C. S.</given-names></name>; <name><surname>Lyoo</surname><given-names>C. H.</given-names></name>; <name><surname>Corona</surname><given-names>W.</given-names></name>; <name><surname>Morse</surname><given-names>C. L.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Hyde</surname><given-names>T.</given-names></name>; <name><surname>Kleinman</surname><given-names>J. E.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>McMahon</surname><given-names>F. J.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name> (<year>2013</year>) <article-title>A genetic polymorphism
for translocator protein 18 kDa affects both in vitro and in vivo
radioligand binding in human brain to this putative biomarker of neuroinflammation</article-title>. <source>J. Cerebr. Blood Flow Metab.</source>
<volume>33</volume>, <fpage>53</fpage>&#x02013;<lpage>58</lpage>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Owen</surname><given-names>D. R. J.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Rabiner</surname><given-names>E. A.</given-names></name>; <name><surname>Bennacef</surname><given-names>I.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Kreisl</surname><given-names>W. C.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name>; <name><surname>Reynolds</surname><given-names>R.</given-names></name>; <name><surname>Matthews</surname><given-names>P. M.</given-names></name>; <name><surname>Parker</surname><given-names>C. A.</given-names></name> (<year>2011</year>) <article-title>Mixed-affinity binding in humans
with 18-kDa translocator protein ligands</article-title>. <source>J.
Nucl. Med.</source>
<volume>52</volume>, <fpage>24</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">21149489</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Owen</surname><given-names>D. R.</given-names></name>; <name><surname>Yeo</surname><given-names>A. J.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Song</surname><given-names>K.</given-names></name>; <name><surname>Wadsworth</surname><given-names>G.</given-names></name>; <name><surname>Lewis</surname><given-names>A.</given-names></name>; <name><surname>Rhodes</surname><given-names>C.</given-names></name>; <name><surname>Pulford</surname><given-names>D. J.</given-names></name>; <name><surname>Bennacef</surname><given-names>I.</given-names></name>; <name><surname>Parker</surname><given-names>C. A.</given-names></name>; <name><surname>StJean</surname><given-names>P. L.</given-names></name>; <name><surname>Cardon</surname><given-names>L. R.</given-names></name>; <name><surname>Mooser</surname><given-names>V. E.</given-names></name>; <name><surname>Matthews</surname><given-names>P. M.</given-names></name>; <name><surname>Rabiner</surname><given-names>E. A.</given-names></name>; <name><surname>Rubio</surname><given-names>J. P.</given-names></name> (<year>2012</year>) <article-title>An 18-kDa translocator
protein (TSPO) polymorphism explains differences in binding affinity
of the PET radioligand PBR28</article-title>. <source>J. Cereb. Blood
Flow Metab.</source>
<volume>32</volume>, <fpage>1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22008728</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Castellano</surname><given-names>S.</given-names></name>; <name><surname>Taliani</surname><given-names>S.</given-names></name>; <name><surname>Milite</surname><given-names>C.</given-names></name>; <name><surname>Pugliesi</surname><given-names>I.</given-names></name>; <name><surname>Da Pozzo</surname><given-names>E.</given-names></name>; <name><surname>Rizzetto</surname><given-names>E.</given-names></name>; <name><surname>Bendinelli</surname><given-names>S.</given-names></name>; <name><surname>Costa</surname><given-names>B.</given-names></name>; <name><surname>Cosconati</surname><given-names>S.</given-names></name>; <name><surname>Greco</surname><given-names>G.</given-names></name>; <name><surname>Novellino</surname><given-names>E.</given-names></name>; <name><surname>Sbardella</surname><given-names>G.</given-names></name>; <name><surname>Stefancich</surname><given-names>G.</given-names></name>; <name><surname>Martini</surname><given-names>C.</given-names></name>; <name><surname>Da Settimo</surname><given-names>F.</given-names></name> (<year>2012</year>) <article-title>Synthesis
and biological evaluation of 4-phenylquinazoline-2-carboxamides designed
as a novel class of potent ligands of the translocator protein</article-title>. <source>J. Med. Chem.</source>
<volume>55</volume>, <fpage>4506</fpage>&#x02013;<lpage>4510</lpage>.<pub-id pub-id-type="pmid">22489952</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Castellano</surname><given-names>S.</given-names></name>; <name><surname>Taliani</surname><given-names>S.</given-names></name>; <name><surname>Viviano</surname><given-names>M.</given-names></name>; <name><surname>Milite</surname><given-names>C.</given-names></name>; <name><surname>Da Pozzo</surname><given-names>E.</given-names></name>; <name><surname>Costa</surname><given-names>B.</given-names></name>; <name><surname>Barresi</surname><given-names>E.</given-names></name>; <name><surname>Bruno</surname><given-names>A.</given-names></name>; <name><surname>Cosconati</surname><given-names>S.</given-names></name>; <name><surname>Marinelli</surname><given-names>L.</given-names></name>; <name><surname>Greco</surname><given-names>G.</given-names></name>; <name><surname>Novellino</surname><given-names>E.</given-names></name>; <name><surname>Sbardella</surname><given-names>G.</given-names></name>; <name><surname>Da Settimo</surname><given-names>F.</given-names></name>; <name><surname>Martini</surname><given-names>C.</given-names></name> (<year>2014</year>) <article-title>Structure-activity
relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide
translocator protein ligands as antiproliferative agents in human
glioblastoma tumors</article-title>. <source>J. Med. Chem.</source>
<volume>57</volume>, <fpage>2413</fpage>&#x02013;<lpage>2428</lpage>.<pub-id pub-id-type="pmid">24580635</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Pike</surname><given-names>V. W.</given-names></name> (<year>1993</year>) <article-title>Positron-emitting
radioligands for studies in vivo&#x02014;probes for human psychopharmacology</article-title>. <source>J. Psychopharmacol.</source>
<volume>7</volume>, <fpage>139</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">22290661</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Laruelle</surname><given-names>M.</given-names></name>; <name><surname>Slifstein</surname><given-names>M.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name> (<year>2003</year>) <article-title>Relationships between radiotracer
properties and image quality in molecular imaging of the brain with
positron emission tomography</article-title>. <source>Mol. Imaging Biol.</source>
<volume>5</volume>, <fpage>363</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">14667491</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Waterhouse</surname><given-names>R. N.</given-names></name> (<year>2003</year>) <article-title>Determination
of lipophilicity and its use as a predictor of blood-brain barrier
penetration of molecular imaging agents</article-title>. <source>Mol.
Imaging Biol.</source>
<volume>5</volume>, <fpage>376</fpage>&#x02013;<lpage>389</lpage>.<pub-id pub-id-type="pmid">14667492</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Pike</surname><given-names>V. W.</given-names></name> (<year>2009</year>) <article-title>PET Radiotracers:
crossing the blood-brain barrier and surviving metabolism</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>30</volume>, <fpage>431</fpage>&#x02013;<lpage>440</lpage>.<pub-id pub-id-type="pmid">19616318</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Logan</surname><given-names>J.</given-names></name>; <name><surname>Fowler</surname><given-names>J. S.</given-names></name>; <name><surname>Volkow</surname><given-names>N. D.</given-names></name>; <name><surname>Wolf</surname><given-names>A. P.</given-names></name>; <name><surname>Dewey</surname><given-names>S. L.</given-names></name>; <name><surname>Schlyer</surname><given-names>D. J.</given-names></name>; <name><surname>MacGregor</surname><given-names>R. R.</given-names></name>; <name><surname>Hitzemann</surname><given-names>R.</given-names></name>; <name><surname>Bendriem</surname><given-names>B.</given-names></name>; <name><surname>Gatley</surname><given-names>S. J.</given-names></name>; <name><surname>Christman</surname><given-names>D. R.</given-names></name> (<year>1990</year>) <article-title>Graphical
analysis of reversible radioligand binding from time-activity measurements
applied to [<italic>N</italic>-<sup>11</sup>C-methyl]-(&#x02212;)-cocaine
PET studies in human subjects</article-title>. <source>J. Cerebr. Blood
Flow Metab.</source>
<volume>10</volume>, <fpage>740</fpage>&#x02013;<lpage>747</lpage>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Cunningham</surname><given-names>V. J.</given-names></name>; <name><surname>Delforge</surname><given-names>J.</given-names></name>; <name><surname>Fujita</surname><given-names>M.</given-names></name>; <name><surname>Gjedde</surname><given-names>A.</given-names></name>; <name><surname>Gunn</surname><given-names>R. N.</given-names></name>; <name><surname>Holden</surname><given-names>J.</given-names></name>; <name><surname>Houle</surname><given-names>S.</given-names></name>; <name><surname>Huang</surname><given-names>S.-C.</given-names></name>; <name><surname>Ichise</surname><given-names>M.</given-names></name>; <name><surname>Iida</surname><given-names>H.</given-names></name>; <name><surname>Ito</surname><given-names>H.</given-names></name>; <name><surname>Kimura</surname><given-names>Y.</given-names></name>; <name><surname>Koeppe</surname><given-names>R. A.</given-names></name>; <name><surname>Knudsen</surname><given-names>G.-M.</given-names></name>; <name><surname>Knuuti</surname><given-names>J.</given-names></name>; <name><surname>Lammertsma</surname><given-names>A. A.</given-names></name>; <name><surname>Laruelle</surname><given-names>M.</given-names></name>; <name><surname>Logan</surname><given-names>J.</given-names></name>; <name><surname>Maguire</surname><given-names>R. P.</given-names></name>; <name><surname>Mintun</surname><given-names>M. A.</given-names></name>; <name><surname>Morris</surname><given-names>E. D.</given-names></name>; <name><surname>Parsey</surname><given-names>R.</given-names></name>; <name><surname>Price</surname><given-names>J. C.</given-names></name>; <name><surname>Slifstein</surname><given-names>M.</given-names></name>; <name><surname>Sossi</surname><given-names>V.</given-names></name>; <name><surname>Suhara</surname><given-names>T.</given-names></name>; <name><surname>Votaw</surname><given-names>J. R.</given-names></name>; <name><surname>Wong</surname><given-names>D. F.</given-names></name>; <name><surname>Carson</surname><given-names>R. E.</given-names></name> (<year>2007</year>) <article-title>Consensus nomenclature for <italic>in vivo</italic> imaging of reversibly binding radioligands</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>27</volume>, <fpage>1533</fpage>&#x02013;<lpage>1539</lpage>.<pub-id pub-id-type="pmid">17519979</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Anderson</surname><given-names>K. B.</given-names></name>; <name><surname>Jenko</surname><given-names>K. J.</given-names></name>; <name><surname>Luckenbaugh</surname><given-names>D. A.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name>; <name><surname>Pike</surname><given-names>V. W.</given-names></name> (<year>2012</year>) <article-title>On quantitative relationships between
drug-like compound lipophilicity and plasma free fraction in monkey
and human</article-title>. <source>J. Pharm. Sci.</source>
<volume>101</volume>, <fpage>1028</fpage>&#x02013;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">22170327</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Shultz</surname><given-names>M. D.</given-names></name> (<year>2013</year>) <article-title>Setting
expectations in molecular optimizations: strengths and limitations
of commonly used composite parameters</article-title>. <source>Bioorg.
Med. Chem. Lett.</source>
<volume>23</volume>, <fpage>5980</fpage>&#x02013;<lpage>5991</lpage>.<pub-id pub-id-type="pmid">24018190</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Cheng</surname><given-names>Y.</given-names></name>; <name><surname>Prusoff</surname><given-names>W. H.</given-names></name> (<year>1973</year>) <article-title>Relationship between constant (K<sub>i</sub>) and the
concentration of inhibitor which causes 50% inhibition (IC<sub>50</sub>) of an enzymatic reaction</article-title>. <source>Biochem. Pharmacol.</source>
<volume>22</volume>, <fpage>3099</fpage>&#x02013;<lpage>3108</lpage>.<pub-id pub-id-type="pmid">4202581</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Christman</surname><given-names>D. R.</given-names></name>; <name><surname>Finn</surname><given-names>R. D.</given-names></name>; <name><surname>Karlstr&#x000f6;m</surname><given-names>K.</given-names></name>; <name><surname>Wolf</surname><given-names>A. P.</given-names></name> (<year>1975</year>) <article-title>The production of
ultra high specific activity <sup>11</sup>C-labeled hydrogen cyanide,
carbon dioxide, carbon monoxide and methane via the <sup>14</sup>N(p,&#x003b1;)<sup>11</sup>C reaction</article-title>. <source>Int. J. Appl. Radiat. Isot.</source>
<volume>26</volume>, <fpage>435</fpage>&#x02013;<lpage>442</lpage>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="weblink" id="cit47"><person-group person-group-type="allauthors"><name><surname>Smith</surname><given-names>D.</given-names></name></person-group> (<year>2008</year>) <article-title>Synthia gets extreme makeover courtesy
of National Instruments</article-title>, pp <fpage>24</fpage>&#x02013;<lpage>25, </lpage><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ftp://ftp.ni.com/pub/branches/.../NIDaysBooklet.pdf">ftp://ftp.ni.com/pub/branches/.../NIDaysBooklet.pdf</uri>.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="book" id="cit48"><person-group person-group-type="allauthors"><name><surname>Bjurling</surname><given-names>P.</given-names></name>, <name><surname>Reineck</surname><given-names>R.</given-names></name>, <name><surname>Westerburg</surname><given-names>G.</given-names></name>, <name><surname>Gee</surname><given-names>A.
D.</given-names></name>, <name><surname>Sutcliffe</surname><given-names>J.</given-names></name>, and <name><surname>L&#x000e5;ngstr&#x000f6;m</surname><given-names>B.</given-names></name></person-group> (<year>1995</year>) <article-title>Synthia, a compact radiochemistry system for automated
production of radiopharmaceuticals</article-title>, in <source>Proceedings&#x02014;Sixth
Workshop on Targetry and Target Chemistry</source> (<person-group person-group-type="editor"><name><surname>Link</surname><given-names>J. M.</given-names></name>, <name><surname>Ruth</surname><given-names>T. J.</given-names></name></person-group>, Eds.), pp <fpage>282</fpage>&#x02013;<lpage>284</lpage>, <publisher-name>TRIUMF</publisher-name>, <publisher-loc>Vancouver</publisher-loc>.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Larsen</surname><given-names>P.</given-names></name>; <name><surname>Ulin</surname><given-names>J.</given-names></name>; <name><surname>Dahlstr&#x000f6;m</surname><given-names>K.</given-names></name>; <name><surname>Jensen</surname><given-names>M.</given-names></name> (<year>1997</year>) <article-title>Synthesis of [<sup>11</sup>C]iodomethane by iodination of [<sup>11</sup>C]methane</article-title>. <source>Appl. Radiat. Isot.</source>
<volume>48</volume>, <fpage>153</fpage>&#x02013;<lpage>157</lpage>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="book" id="cit50"><person-group person-group-type="allauthors"><name><surname>Clark</surname><given-names>J. D.</given-names></name>, <name><surname>Baldwin</surname><given-names>R. L.</given-names></name>, <name><surname>Bayne</surname><given-names>K. A.</given-names></name>, <name><surname>Brown</surname><given-names>M. J.</given-names></name>, <name><surname>Gebhart</surname><given-names>G. F.</given-names></name>, <name><surname>Gonder</surname><given-names>J. C.</given-names></name>, <name><surname>Gwathmey</surname><given-names>J. K.</given-names></name>, <name><surname>Keeling</surname><given-names>M. E.</given-names></name>, <name><surname>Kohn</surname><given-names>D. F.</given-names></name>, <name><surname>Robb</surname><given-names>J. W.</given-names></name>, <name><surname>Smith</surname><given-names>O. A.</given-names></name>, <name><surname>Steggerda</surname><given-names>J.-A. D.</given-names></name>, and <name><surname>VandeBer</surname><given-names>J. L.</given-names></name></person-group> (<year>1996</year>) <source>Guide for the Care and Use of Laboratory Animals</source>, <publisher-name>National Academy Press</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Gandelman</surname><given-names>M. S.</given-names></name>; <name><surname>Baldwin</surname><given-names>R. M.</given-names></name>; <name><surname>Zoghbi</surname><given-names>S. S.</given-names></name>; <name><surname>Zea-Ponce</surname><given-names>Y.</given-names></name>; <name><surname>Innis</surname><given-names>R. B.</given-names></name> (<year>1994</year>) <article-title>Evaluation of ultrafiltration for the free-fraction
determination of single photon emission computed tomography (SPECT)
radiotracers: &#x003b2;-CIT, IBF, and iomazenil</article-title>. <source>J. Pharm. Sci.</source>
<volume>83</volume>, <fpage>1014</fpage>&#x02013;<lpage>1019</lpage>.<pub-id pub-id-type="pmid">7965658</pub-id></mixed-citation></ref></ref-list></back></article>